Almirall SA ((GB:0O9B)), Almirall ((DE:E2Z)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Almirall S.A. is conducting a study titled ‘Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting – Light Version’ to explore the link between clinical symptoms and quality of life in patients treated with Tildrakizumab for moderate to severe plaque psoriasis. The study aims to provide insights into patient-reported outcomes in real-world settings.
The intervention being tested is Tildrakizumab, a drug used in clinical practice to treat moderate to severe plaque psoriasis. The study observes patients receiving this treatment to assess its impact on their wellbeing.
This observational study follows a cohort model and is prospective in nature. It does not involve random allocation or masking, focusing instead on real-world data collection to understand the primary purpose of improving patient quality of life.
The study began on April 4, 2024, with primary completion expected by June 28, 2024. The latest update was submitted on June 23, 2025, indicating ongoing data collection and analysis.
The study’s findings could influence Almirall’s stock performance by providing evidence of Tildrakizumab’s effectiveness, potentially boosting investor confidence. In the competitive landscape of psoriasis treatments, positive results may enhance Almirall’s market position.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.